This Week in Biotech: Celldex Buddies Up While Isis' Experimental Diabetes Therapy Impresses

Celldex finds a partner, Isis dazzles Wall Street with type 2 diabetes data, and Novartis lays an egg. These are just some of this week's top biotech stories.

May 17, 2014 at 12:15PM

With the SPDR S&P Biotech Index up 15% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies that made waves in the sector last week.

The buddy system
Although we saw no megamergers this past week, there was one deal that caught the attention of investors and sent one mid-cap biotech stock screaming higher.

On Wednesday morning clinical-stage biopharmaceutical company Celldex Therapeutics (NASDAQ:CLDX) announced a clinical trial collaboration with Bristol-Myers Squibb that'll combine Celldex's investigational CD27-targeting antibody known as varlilumab with Bristol's prized experimental anti-PD-1 immunotherapy nivolumab. These phase 1/2 studies will be targeted at a number of solid tumor types, including non-small cell lung cancer and colorectal cancer, and should begin by the fourth quarter of this year. Under the terms of the deal Celldex will receive a one-time $5 million upfront payment, and it could garner an experienced marketing partner if these combo trials prove successful. Investors, of course, should keep in mind that Celldex is already carrying around a $1.2 billion valuation despite no recurring cash flow, so much of this recent optimism appears to be baked into its share price already.

Novartis Research
Source: Novartis.

All holds barred
The big news of the week might appear to be Halozyme Therapeutics' (NASDAQ:HALO) first-quarter report after the bell on Monday, but it was a simple paragraph buried within that report that stirred investors' enthusiasm. As noted by Dr. Helen Torley, the President and CEO of Halozyme,

In early April, we temporarily halted dosing of PEGPH20 in Study 202 so the Data Monitoring Committee (DMC) could evaluate a possible imbalance in the rate of thromboembolic events between the drug arm and the control arm in the trial. We have since provided the DMC with requested information including an amended study protocol, and the DMC has informed us that they now support continued enrollment of patients and dosing of PEGPH20 in the trial with the proposed study modifications. 

In other words, the hold on PEGPH20, which really shouldn't have been a huge factor in Halozyme's valuation back in April, but which nonetheless rocked its share price, has been removed and Halozyme is free to study this pancreatic cancer-focused therapy in a phase 2a trial. Following the approval of MabThera SC in Europe and its positive results from the CONSISTENT-1 trial, I'd suggest Halozyme could have some decent upside for patient long-term investors.

Isis' incredible results
Despite flying largely under the radar, Isis Pharmaceuticals (NASDAQ:ISIS) phase 2 results on ISIS-GCGR, an experimental type 2 diabetes drug, this past Wednesday were simply phenomenal.

According to its results, ISIS-GCGR achieved absolute mean hemoglobin A1c (HbA1c) reductions of two percentage points in type 2 diabetes patients from baseline in just 13 weeks. In addition, ISIS-GCGR was associated with an increase in GLP-1 levels which would be expected to enhance insulin secretion in the pancreas, and help to preserve pancreatic function in order to restore glycemic balance.  Recent clinical studies from competitors have yielded HbA1c reductions in the 0.5%-1% range, so its greater than 1% reduction witnessed in the 100 mg and 200 mg cohorts is incredibly encouraging and speaks to the potential of Isis' in-house development drug development platform. Do yourself a favor and keep a close eye on this diabetes therapy and Isis moving forward.

Novartis Researcher

Source: Novartis.

Early success
Shares of Northwest Biotherapeutics (NASDAQ:NWBO) were whipsawed to end the week with the company on Thursday morning announcing positive results from its first revealed case study featuring its cancer immunotherapy DCVax-Direct on a patient with sarcoma.

According to its press release, this patient in question received three DCVax-Direct injections which demonstrated a partial collapse of the injected tumor via an MRI scan, as well as the potentially early signs of tumor shrinkage in a non-injected metastatic growth in the patients' lungs via CT scan. As I pointed out on Thursday, we should still keep in mind that this is very early data, and it's also handpicked data by NW Bio in that we haven't been told how any other patients are performing, so keep that bias in mind as you assess the performance of DCVax-Direct. However, with the American Society of Clinical Oncology conference set to kick off in less than two weeks we're likely to know a bit more then which could make valuing the company a bit easier.  

Sent packing
Finally, and this should really come as no surprise to those who've been following the development of Novartis' (NYSE:NVS) experimental acute heart failure drug RLX030 (also known as serelaxin), the Food and Drug Administration on Friday officially gave its thumbs-down to serelaxin and sent Novartis a complete response letter. Again, not a huge shock given that in May the FDA's advisory panel voted unanimously against recommending the prospective therapy for approval.

RLX030 is an interesting case as it's also a breakthrough therapy designated drug, and as Novartis notes, it plans to continue development of the drug. Novartis' plans include enrolling more than 6,300 patients in its RELAX-AHF-2 trial which it anticipates will add to the encouraging results from its original trial and appease the FDA into an eventual approval. Given the prevalence of acute heart failure cases in the U.S. and throughout the world, if approved RLX030 could have annual peak sales potential of $1 billion or greater, so it's certainly a therapy Novartis doesn't want to easily give up on. For now this isn't a huge surprise for Novartis shareholders, but they'll want to keep their eyes peeled on this large trials' development.

We saw some big gains this week, but even these companies could struggle to keep pace with this top stock over the long run
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information